A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, phase Ib/II study to examine the safety, tolerability and preliminary
efficacy of one cycle of Ad-RTS-hIL-12 immunotherapy in women with advanced breast cancer and
pre-study SD or PR after completion of a minimum 12 week course of standard first- or
second-line chemotherapy. The patient population will include patients with locally advanced
or metastatic breast cancer of all subtypes.